Is Strides Pharma overvalued or undervalued?

As of 31 October 2025, Strides Pharma's valuation grade has moved from very attractive to attractive, indicating a shift in market perception. The company is currently fairly valued, with a PE ratio of 19.76, an EV to EBITDA of 11.72, and a PEG ratio of 0.00, which suggests strong earnings growth potential relative to its price.
In comparison to its peers, Strides Pharma's valuation metrics appear more favorable; for instance, Sun Pharma has a PE ratio of 35.35, while Cipla stands at 22.29. Additionally, Strides Pharma's return performance has significantly outpaced the Sensex, with a year-to-date return of 42.13% compared to the Sensex's 7.42%. This performance reinforces the notion that Strides Pharma is positioned well within the market, despite its recent downgrade in valuation grade.